Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Metadata
Title
Promotion of colon cancer metastases in rat liver by fish oil diet is not due to reduced stroma formation
Authors
Lars Klieverik
Olav Fehres
Patrizia Griffini
Cornelis J.F. Van Noorden
Wilma M. Frederiks
Publication date
01-09-2000
Publisher
Kluwer Academic Publishers
Published in
Clinical & Experimental Metastasis / Issue 5/2000
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1023/A:1010813916024

Other articles of this Issue 5/2000

Clinical & Experimental Metastasis 5/2000 Go to the issue

OriginalPaper

Differences in association of the serine/threonine protein phosphatase PP-2A with microtubules of metastatic and nonmetastatic tumor cells

OriginalPaper

The role of matrilysin (MMP-7) in leukaemia cell invasion

OriginalPaper

Fibronectin activates matrix metalloproteinase-9 secretion via the MEK1-MAPK and the PI3K-Akt pathways in ovarian cancer cells

OriginalPaper

Antimetastatic efficacy of adjuvant gemcitabine in a pancreatic cancer orthotopic model

OriginalPaper

Dual X-ray absorptiometry detects disease- and treatment-related alterations of bone density in prostate cancer patients

OriginalPaper

Dietary 4-HPR suppresses the development of bone metastasis in vivo in a mouse model of prostate cancer progression
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits